- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT04831853
Self- Versus Conventional-swabbing for COVID-19 Screening (COVISWAB) (COVISWAB)
Comparison for Sensitivity and Tolerance of Self-swabbing and Conventional Nasopharyngeal Swabbing for SARS-CoV-2 Detection for Pain, Discomfort and Acceptability: a Randomized Controlled Non-inferiority Study
Self-swabbing requires less personal protective equipment and could allow to test more people and even to do quick self-diagnosis if antigenic tests are available.
In a preliminary study on 190 medical students, the investigators have shown that self and conventional swabbing were identically well-accepted with equivalent level of pain and discomfort induced by swabbing. In a sub-group of this sample, the investigators have shown that the quality of the 2 sampling methods were equivalent.
The goal of this large study in the general population is to confirm these findings in an adequately powered study. Such results would allow to develop self-swabbing for large screening campaigns and eventually self-diagnosis using antigenic tests.
A tanulmány áttekintése
Állapot
Körülmények
Részletes leírás
All consecutive subjects coming to the 2 dedicated centers for COVID-19 screening in Clermont-Ferrand University hospital (one for medical students and one for the general population) will be asked to be included in the present study. They will be randomly assigned to either supervised self-swabbing followed by conventional swabbing led by a healthcare professional or the other way round.
All the subjects will have to complete a brief questionnaire including demographical characteristics (age, sex, height, weight, eye color), potential symptoms (asthenia, fever, anosmia…) anticipated pain and discomfort and previous nasopharyngeal swabbing experience. Pain, discomfort and overall acceptability of the procedure will be completed just after completion of the swabbing.
Tanulmány típusa
Beiratkozás (Várható)
Fázis
- Nem alkalmazható
Kapcsolatok és helyek
Tanulmányi helyek
-
-
-
Clermont-Ferrand, Franciaország, 63000
- CHU de Clermont-Ferrand
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
Egészséges önkénteseket fogad
Tanulmányozható nemek
Leírás
Inclusion Criteria:
- Any subject coming for nasopharyngeal swabbing for SARS-CoV-2 screening
- Fluent in French (both oral and written)
- Able to give an eclaired consent
Exclusion Criteria:
- Contra-indication to nasopharyngeal swabbing
- Refusal to participate
- Pregnant women
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Diagnosztikai
- Kiosztás: Véletlenszerűsített
- Beavatkozó modell: Párhuzamos hozzárendelés
- Maszkolás: Nincs (Open Label)
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
---|---|
Kísérleti: Supervised self-swabbing followed by conventional swabbing
the subjects will first benefit from a 5 minutes explanation on how to perform self-swabbing and will then performed the swabbing under the supervision of a trained healthcare professional
|
Patient realises the nasal swabbing himself first, then undergoes conventionnal swabbing
|
Kísérleti: Conventional swabbing followed by supervised self-swabbing
the subject will undergo conventional nasopharyngeal swabbing performed by a trained healthcare professional first.
|
patient undergoes conventionnal swabbing first then realises the nasal swabbing himself
|
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
---|---|---|
Non-inferiority of self-swabbing compared to conventional swabbing concerning diagnosis sensitivity
Időkeret: 5 minutes after the end of the procedure of nasopharyngeal swabbing
|
assessed using consistency of COVID-19 RT-PCR results for both sampling modalities (Self- swabbing versus conventional-swabbing).
If non-inferiority is confirmed on this criterion, pain will be tested.
|
5 minutes after the end of the procedure of nasopharyngeal swabbing
|
Másodlagos eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
---|---|---|
Correlation between age, sex and swabbing-induced pain
Időkeret: 5 minutes after the end of the procedure
|
Score on the pain numeric rating scale (0 to 10; higher scores meaning more pain)
|
5 minutes after the end of the procedure
|
Correlation between eye color and swabbing-induced pain
Időkeret: 5 minutes after the end of the procedure
|
Eye-color self-reported by the subject on a validated 14 item scale and pain score on the numeric rating scale (NRS) (0 to 10; higher scores meaning more pain)
|
5 minutes after the end of the procedure
|
Correlation between eye color and swabbing-induced discomfort
Időkeret: 5 minutes after the end of the procedure
|
Eye-color self-reported by the subject on a validated 14 item scale and discomfort score on numeric rating scale (0 to 10; higher scores meaning more discomfort)
|
5 minutes after the end of the procedure
|
Correlation between symptoms (fever, headache, asthenia, anosmia, agueusia, cough, dyspnea, muscle pain, sore throat, diarrhea) and swabbing-induced pain
Időkeret: 5 minutes after the end of the procedure
|
symptoms self-reported by the subject and pain score on numeric rating scale (0 to 10; higher scores meaning more pain)
|
5 minutes after the end of the procedure
|
Correlation between body mass index and swabbing-induced pain
Időkeret: 5 minutes after the end of the procedure
|
symptoms self-reported by the subject and pain score on numeric rating scale (0 to 10; higher scores meaning more pain)
|
5 minutes after the end of the procedure
|
Correlation between anticipated pain and actual pain
Időkeret: 5 minutes after the end of the procedure
|
anticipated and actual pain self-reported on numeric rating scale (0 to 10; higher scores meaning more pain)
|
5 minutes after the end of the procedure
|
Correlation between anticipated discomfort and actual discomfort.
Időkeret: 5 minutes after the end of the procedure
|
anticipated and actual discomfort self-reported on numeric rating scale (0 to 10; higher scores meaning more pain)
|
5 minutes after the end of the procedure
|
Richness assessment for respiratory cells
Időkeret: Day 0
|
Ct value of beta-globin gene
|
Day 0
|
Non-inferiority of self-swabbing compared to conventional swabbing concerning pain
Időkeret: 5 minutes after the end of the procedure of nasopharyngeal swabbing
|
assessed using a Numerical Rating Scale (0 indicating no pain and 10 the worst imaginable pain).
If non-inferiority is confirmed on this criterion, discomfort will be tested
|
5 minutes after the end of the procedure of nasopharyngeal swabbing
|
Non-inferiority of self-swabbing compared to conventional swabbing concerning pain discomfort
Időkeret: 5 minutes after the end of the procedure of nasopharyngeal swabbing
|
assessed using a Numerical Rating Scale (0 indicating no discomfort and 10 the worst imaginable discomfort).
If non-inferiority is confirmed on this criterion, acceptability will be tested
|
5 minutes after the end of the procedure of nasopharyngeal swabbing
|
Non-inferiority of self-swabbing compared to conventional swabbing concerning acceptability
Időkeret: 5 minutes after the end of the procedure of nasopharyngeal swabbing
|
assessed using a Numerical Rating Scale (0 indicating that the procedure is not acceptable at all and 10 that the procedure is perfectly well accepted).
|
5 minutes after the end of the procedure of nasopharyngeal swabbing
|
Együttműködők és nyomozók
Nyomozók
- Kutatásvezető: Xavier MOISSET, University Hospital, Clermont-Ferrand
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete (Várható)
Elsődleges befejezés (Várható)
A tanulmány befejezése (Várható)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Tényleges)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
További vonatkozó MeSH feltételek
Egyéb vizsgálati azonosító számok
- RBHP 2020 MOISSET 2
- 2020-A02913-36 (Egyéb azonosító: ANSM)
Gyógyszer- és eszközinformációk, tanulmányi dokumentumok
Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz
Egy amerikai FDA által szabályozott eszközterméket tanulmányoz
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .
Klinikai vizsgálatok a Covid19
-
Anavasi DiagnosticsMég nincs toborzás
-
Ain Shams UniversityToborzás
-
Israel Institute for Biological Research (IIBR)Befejezve
-
Colgate PalmoliveBefejezve
-
Christian von BuchwaldBefejezve
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdAktív, nem toborzó
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitätsspital ZürichJelentkezés meghívóval
-
Alexandria UniversityBefejezve
-
Henry Ford Health SystemBefejezve